<DOC>
	<DOC>NCT00052039</DOC>
	<brief_summary>Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.</brief_summary>
	<brief_title>A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
</DOC>